Breast tissue expansion device maker AirXpanders still has about $4.8 million to go to top off a hoped-for $9 million funding, which has attracted 6 unnamed investors so far.

The funding round consists of equity, options to acquire other securities, Series E preferred stock and common stock, according to an SEC filing.

AirXpanders in October 2012 won CE Mark approval for its AeroForm device, which currently has investigational device exemption in the U.S. This device expands breast tissue using a patient-controlled remote, replacing the saline injections currently given by plastic surgeons in preparation for reconstructive surgery.

The company closed a $10 million Series D round last year to support its investigational device studies.